David A. Siegel Bridge Bio Pharma, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,684,055 shares of BBIO stock, worth $92.7 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
1,684,055
Previous 273,155
516.52%
Holding current value
$92.7 Million
Previous $9.44 Million
670.14%
% of portfolio
0.16%
Previous 0.02%
Shares
18 transactions
Others Institutions Holding BBIO
# of Institutions
410Shares Held
187MCall Options Held
11.3MPut Options Held
1.91M-
Viking Global Investors LP18.6MShares$1.02 Billion2.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.5MShares$907 Million0.01% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY13.3MShares$730 Million22.63% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$685 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X09.28MShares$510 Million0.21% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $8.16B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...